Abstract library

19 results for "simultaneous".
#1168 Simultaneous Large Cell Neuroendocrine Carcinoma and Adenocarcinoma of the Stomach: A Case Report and Literature Review
Introduction: Large cell neuroendocrine carcinoma (LCNEC) of the stomach is rare. Gastric NEC occasionally has another component, such as adenocarcinoma, in the same tumor. However, the concurrent occurrence of LCNEC and adenocarcinoma at different sites in the stomach is extremely rare.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD Shoichi Nakazuru
#1414 Non-functioning Adrenal Composite Pheochromocytoma-Ganglioneuroma Simultaneous with Subclinical Cushing's Syndrome Due to Contralateral Adrenal Hyperplasia - An Unusual Presentation
Introduction: “Composite” pheochromocytoma is a rare tumor, consisting of pheochromocytoma and neuroblastic tumors. The definite diagnosis is histological. Subclinical Cushing's syndrome refers to autonomous glucocorticoid production without specific signs and symptoms of Cushing's syndrome.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Antonia Ema Kiraly
#2206 Metastatic Neuroendocrine Tumor with Unknown Primary Site Presenting Simultaneously with Prostate Adenocarcinoma
Introduction: Neuroendocrine tumors (NET) arise from a variety of different organs and have a steadily increasing incidence in the last 3 decades. 13% of NETs have unknown primary sites.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Oana-Stefana Enache
#66 Adrenocortical cancer: a therapeutic approach with everolimus (RAD001)
Introduction: Adrenocortical cancer (ACC) is a rare disease with very poor outcome. ACC responds poorly to standard chemotherapy. Mitotane, used as adjuvant therapy to surgery, prolongs recurrence-free survival, but the response is limited to 23% of patients and resistance occurs in the majority of patients (1). There is no curative therapy for ACC. Pre-clinical studies have shown involvement of both IGF-2/IGF-1R and Akt/mTOR pathways in ACC, and IGF-1R and mTOR inhibitors inhibited cell proliferation of human adrenocortical carcinoma cell lines in vitro (2,3,4).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Maria Gueorguiev
#340 Aggressive Somatostatinoma, with Associated Pheocromocytoma in a Neurofibromatosis Patient
Introduction: Neurofibromatosis is associated with a neuroendocrine phenotype as pheocromocytoma, primary hyperparathyroidism and gastropancreatic neuroendocrine tumors.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Catalina Poiana
Authors: Poiana C, Carsote M, Radoi V, Ene C, ...
#349 Gastrointestinal Stromal Tumor (GIST) Of The Esophagus In A Patient With MEN-1 And-Related Pancreatic Gastrinoma
Introduction: Both Multiple Endocrine Neoplasia type 1 (MEN-1; OMIM #613733)-related-gastrinomas and Gastrointestinal Stromal Tumors (GISTs; OMIM #606764) are rare neoplasms and their association has been rarely reported so far.
Conference:
Category: Basic
Presenting Author: Dr Roberta E Rossi
#387 Combined Blockade of Several Signalling Pathways Shows Marked Anti-Tumor Potential in Two Novel Mouse Phaeochromocytoma Cell Lines
Introduction: The current study explores novel targeted therapies for malignant pheochromocytomas (PCCs) and paragangliomas, utilizing a more benign (MPC) and a more malignant (MTT) PCC cell line. We have previously shown that the dual PI3K/mTORC1 inhibitor NVP-BEZ235 significantly reduced MPC and MTT cell viability, but increased ERK signalling.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Svenja Noelting
#426 An Esophageal Gastrointestinal Stromal Tumor (GIST) in a Patient with MEN-1 Related Pancreatic Gastrinoma
Introduction: Both multiple endocrine neoplasia type 1 (MEN1)-related-gastrinomas and Gastrointestinal Stromal Tumors (GISTs) are rare neoplasms, and their association has been rarely reported.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Roberta E Rossi
#629 Targeting Chaperone Activity and Chaperone Expression in Human GEP-NET Cells Can Repress Their Proliferation and Sensitize Them to Chemotherapy
Introduction: New approaches for better treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are acutely needed. Inhibitors of chaperone activity of heat shock protein 90 (Hsp90) seem to be promising agents but they upregulate cytoprotective chaperones Hsp70 and Hsp27.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Anna Demidkina
#647 Reducing the Risk of Tuberculosis Reactivation when Administering Everolimus for a Pancreatic Neuroendocrine Tumor: A Case Report
Introduction: Everolimus can potentially reactivate tuberculosis (TB) through immunosuppression. This was recently reported to have occurred in a kidney transplant recipient. To date, no clear strategy has been developed for reducing the risk of TB reactivation during everolimus treatment.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: MD Takeshi Tamura
Keywords: everolimus, NET, LTBI